Same-Day Discharge Following Catheter Ablation of Atrial Fibrillation in the United States
Abstract Body (Do not enter title and authors here): Introduction Patients undergoing atrial fibrillation (AF) ablation have historically been hospitalized overnight or longer post-procedure. We conducted this study to characterize national rates of same-day discharge, associated clinical factors, variation across hospitals and in-hospital outcomes.
Methods The NCDR AF Ablation Registry was used to identify all index procedures from January 1st, 2016, to June 30th, 2023. Patients were stratified by post-procedure disposition into 3 cohorts: (1) same-day discharge, (2) overnight hospitalization (<1-day) or (3) >1-day hospitalization. Rates of same-day discharge, associated clinical factors, hospital-level variation and unadjusted post-procedural complication rates were analyzed.
Results Among 139,391 patients who underwent index AF ablation across 197 hospitals in the US, 51622 (37.0%) were discharged the same-day, 78220 (56.1%) hospitalized overnight and 9549 (6.9%) hospitalized for >1-day post-procedure. Shown in Figure 1, the rate of same-day discharge increased from 0.99% (Quarter 1 of 2016) to 62.3% (Q2 2023), p<0.0001 for trend, with a sharp rise in Q1 of 2020 and corresponding decline in those hospitalized overnight (83.3% in Q1 2016 to 32.9% Q2 2023, p<0.0001 for trend). The quarter during which AF ablation procedure was conducted was associated with same-day discharge (OR 1.26, 95% CI 1.256-1.264, Figure 2). In contrast, Black race (OR 0.71, 95% CI 0.65-0.78), persistent AF classification (OR 0.85, 95% CI 0.82-0.88) and prior non-AF catheter ablation (OR 0.89, 95% CI 0.85-0.93) favored overnight hospitalization. Variation in same-day discharge across hospitals was significant (MOR 4.12, 95% CI 3.48-4.79). Aggregate major and overall in-hospital complication rates were 0.70% and 2.13%, respectively. In comparison, major and overall complication rates were 0.03% and 0.19% for same-day discharge and 0.24% and 0.98% for overnight hospitalization.
Conclusion Rates of same-day discharge following AF ablation increased over time and surpassed overnight hospitalization by Q1 2021. Those with paroxysmal AF and fewer comorbid conditions were more likely to undergo same-day discharge with substantial variation across hospitals. Peri-procedural complication rates of those undergoing same day discharge were comparable to overnight hospitalization. With substantial growth in same-day discharge and development of outpatient or ambulatory procedural centers, our findings may assist future procedural policy development.
Sandhu, Amneet
( UNIVERSITY OF COLORADO
, Denver
, Colorado
, United States
)
Freeman, James
( Yale University School of Medicine
, New Haven
, Connecticut
, United States
)
Bradley, Steven
( MINNEAPOLIS HEART INSTITUTE
, Minneapolis
, Minnesota
, United States
)
Rao, Sunil
( NYU Langone Health System
, New York
, North Carolina
, United States
)
Hernandez, Adrian
( Duke Clinical Research Institute
, Durham
, North Carolina
, United States
)
Tzou, Wendy
( UNIVERSITY OF COLORADO
, Aurora
, Colorado
, United States
)
Varosy, Paul
( VAECHCS - University of CO
, Aurora
, Colorado
, United States
)
Hess, Paul
( EASTERN COLORADO HEALTH CARE SYSTEM
, Aurora
, Colorado
, United States
)
Qin, Li
( Yale University School of Medicine
, New Haven
, Connecticut
, United States
)
Minges, Karl
( Yale University School of Medicine
, New Haven
, Connecticut
, United States
)
Zimmerman, Sarah
( Yale University School of Medicine
, New Haven
, Connecticut
, United States
)
Borne, Ryan
( University of Colorado Health
, Colorado Springs, CO
, Colorado
, United States
)
Polsinelli, Vincenzo
( UNIVERSITY OF COLORADO
, Denver
, Colorado
, United States
)
Ho, Michael
( Rocky Mountain VA Medical Center
, Aurora
, Colorado
, United States
)
Hsu, Jonathan
( UNIVERSITY OF CALIFORNIA SAN DIEGO
, La Jolla
, California
, United States
)
Al-khatib, Sana
( DUKE UNIVERSITY MEDICAL CENTER
, Durham
, North Carolina
, United States
)
Author Disclosures:
Amneet Sandhu:DO NOT have relevant financial relationships
| James Freeman:DO have relevant financial relationships
;
Advisor:Boston Scientific:Active (exists now)
; Advisor:PaceMate:Active (exists now)
; Advisor:Abbott:Active (exists now)
; Advisor:Medtronic:Active (exists now)
; Advisor:Biosense Webster:Active (exists now)
| Steven Bradley:DO NOT have relevant financial relationships
| Sunil Rao:DO NOT have relevant financial relationships
| Adrian Hernandez:DO have relevant financial relationships
;
Researcher:AstraZeneca:Active (exists now)
; Researcher:Verve:Active (exists now)
; Researcher:Intellia:Active (exists now)
; Researcher:NovoNordisk:Active (exists now)
; Researcher:Merck:Active (exists now)
; Researcher:Novartis:Active (exists now)
; Researcher:Cytokinetics:Active (exists now)
; Researcher:Amgen:Active (exists now)
; Researcher:Boehringer Ingelheim:Active (exists now)
; Researcher:Bayer:Active (exists now)
| Wendy Tzou:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Advisor:Kardium:Active (exists now)
; Advisor:Biosense Webster:Active (exists now)
; Advisor:Medtronic:Active (exists now)
; Speaker:Medtronic:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Speaker:Boston Scientific:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Speaker:Biotronik:Active (exists now)
; Consultant:Biotronik:Active (exists now)
; Speaker:Biosense Webster:Active (exists now)
; Advisor:Biosense Webster:Active (exists now)
; Consultant:Biosense Webster:Active (exists now)
; Research Funding (PI or named investigator):Abbott:Active (exists now)
; Speaker:Abbott:Active (exists now)
| Paul Varosy:No Answer
| Paul Hess:DO NOT have relevant financial relationships
| Li Qin:No Answer
| Karl Minges:DO NOT have relevant financial relationships
| Sarah Zimmerman:DO NOT have relevant financial relationships
| Ryan Borne:DO NOT have relevant financial relationships
| Vincenzo Polsinelli:DO NOT have relevant financial relationships
| Michael Ho:No Answer
| Jonathan Hsu:DO have relevant financial relationships
;
Speaker:Medtronic:Active (exists now)
; Research Funding (PI or named investigator):Biosense-Webster:Past (completed)
; Research Funding (PI or named investigator):Biotronik:Past (completed)
; Speaker:Zoll Medical:Active (exists now)
; Speaker:iRhythm:Active (exists now)
; Speaker:Biosense-Webster:Active (exists now)
; Speaker:Viz.AI:Active (exists now)
; Speaker:Altathera Pharmaceuticals:Active (exists now)
; Speaker:Milestone:Active (exists now)
; Speaker:Sanofi:Active (exists now)
; Speaker:Bristol-Myers Squibb:Active (exists now)
; Speaker:Janssen Pharmaceuticals:Active (exists now)
; Speaker:Biotronik:Active (exists now)
; Speaker:Boston Scientific:Active (exists now)
; Speaker:Abbott:Active (exists now)
| Sana Al-Khatib:DO NOT have relevant financial relationships